Mereo BioPharma Group plc Debt-to-equity in % from Q3 2024 to Q3 2025

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Mereo BioPharma Group plc quarterly Debt-to-equity history and growth rate from Q3 2024 to Q3 2025.
  • Mereo BioPharma Group plc Debt-to-equity for the quarter ending September 30, 2025 was 17.6 %, a 72% decline year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)

Mereo BioPharma Group plc Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q3 2025 17.6 -45.4 -72% Sep 30, 2025
Q2 2025 47.1 Jun 30, 2025
Q1 2025 45.1 Mar 31, 2025
Q4 2024 56.6 Dec 31, 2024
Q3 2024 63.1 Sep 30, 2024
* An asterisk sign (*) next to the value indicates that the value is likely invalid.